更汀蘆單抗

更汀蘆單抗（INN：Gantenerumab）是由羅氏製藥公司開發的一種用於治療阿爾茨海默病的單克隆抗體。^[1][2]

更汀蘆單抗

更汀蘆單抗（藍色）的Fab片段（英語：Fragment antigen-binding）包圍並結合Aβ(1–11)原纖維（亮綠色）。 PDB 5CSZ.
單克隆抗體
種類	完整抗體
目標	β澱粉樣蛋白（Aβ40/42）
臨床資料
ATC碼	未分配
法律規範狀態
法律規範	Investigational
識別資訊
CAS號	1043556-46-2  N
ChemSpider	none
UNII	4DF060P933
KEGG	D09680 Y
化學資訊
化學式	C6496H10072N1740O2024S42
摩爾質量	146.3 kg/mol (peptide)

更汀蘆單抗結合併清除聚集的β澱粉樣蛋白纖維。^[3]

更汀蘆單抗的III期臨床試驗因缺乏療效而提前停止。^[4]更汀蘆單抗也在患有阿爾茨海默病高風險的年輕患者中進行了評估，^[5]但經過五年的治療，該藥物對減緩患者認知能力下降幾乎沒有作用。^[6]

參考資料

1. Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab (PDF). American Medical Association. [2023-12-06]. （原始內容存檔 (PDF)於2012-02-20）.
2. International Nonproprietary Names for Pharmaceutical Substances (INN) (PDF). World Health Organization. （原始內容 (PDF)存檔於2012-02-11）.
3. Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy. January 2018, 18 (1): 25–35. PMID 29037101. S2CID 4795458. doi:10.1080/14712598.2018.1389885.
4. Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. December 2017, 9 (1): 95. PMC 5723032 . PMID 29221491. doi:10.1186/s13195-017-0318-y .
5. Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
6. Kolata G. An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'. The New York Times. 10 February 2020 [2023-12-06]. （原始內容存檔於2023-12-07）.